Biocompatible anionic polymeric microspheres as priming delivery system for effetive HIV/AIDS Tat-based vaccines.

Autor: Titti F; National AIDS Center, Istituto Superiore di Sanità, Rome, Italy., Maggiorella MT; National AIDS Center, Istituto Superiore di Sanità, Rome, Italy., Ferrantelli F; National AIDS Center, Istituto Superiore di Sanità, Rome, Italy., Sernicola L; National AIDS Center, Istituto Superiore di Sanità, Rome, Italy., Bellino S; National AIDS Center, Istituto Superiore di Sanità, Rome, Italy., Collacchi B; National AIDS Center, Istituto Superiore di Sanità, Rome, Italy., Fanales Belasio E; National AIDS Center, Istituto Superiore di Sanità, Rome, Italy., Moretti S; National AIDS Center, Istituto Superiore di Sanità, Rome, Italy., Pavone Cossut MR; National AIDS Center, Istituto Superiore di Sanità, Rome, Italy., Belli R; National AIDS Center, Istituto Superiore di Sanità, Rome, Italy., Olivieri E; National AIDS Center, Istituto Superiore di Sanità, Rome, Italy., Farcomeni S; National AIDS Center, Istituto Superiore di Sanità, Rome, Italy., Compagnoni D; National AIDS Center, Istituto Superiore di Sanità, Rome, Italy., Michelini Z; National AIDS Center, Istituto Superiore di Sanità, Rome, Italy., Sabbatucci M; National AIDS Center, Istituto Superiore di Sanità, Rome, Italy., Sparnacci K; Department of Environmental and Live Science, University of East Piemonte, Alessandria, Italy., Tondelli L; I.S.O.F., Consiglio Nazionale delle Ricerche, Bologna, Italy., Laus M; Department of Environmental and Live Science, University of East Piemonte, Alessandria, Italy., Cafaro A; National AIDS Center, Istituto Superiore di Sanità, Rome, Italy., Caputo A; Department of Molecular Medicine, University of Padova, Padova, Italy., Ensoli B; National AIDS Center, Istituto Superiore di Sanità, Rome, Italy.
Jazyk: angličtina
Zdroj: PloS one [PLoS One] 2014 Oct 30; Vol. 9 (10), pp. e111360. Date of Electronic Publication: 2014 Oct 30 (Print Publication: 2014).
DOI: 10.1371/journal.pone.0111360
Abstrakt: Here we describe a prime-boost regimen of vaccination in Macaca fascicularis that combines priming with novel anionic microspheres designed to deliver the biologically active HIV-1 Tat protein and boosting with Tat in Alum. This regimen of immunization modulated the IgG subclass profile and elicited a balanced Th1-Th2 type of humoral and cellular responses. Remarkably, following intravenous challenge with SHIV89.6Pcy243, vaccinees significantly blunted acute viremia, as compared to control monkeys, and this control was associated with significantly lower CD4+ T cell depletion rate during the acute phase of infection and higher ability to resume the CD4+ T cell counts in the post-acute and chronic phases of infection. The long lasting control of viremia was associated with the persistence of high titers anti-Tat antibodies whose profile clearly distinguished vaccinees in controllers and viremics. Controllers, as opposed to vaccinated and viremic cynos, exhibited significantly higher pre-challenge antibody responses to peptides spanning the glutamine-rich and the RGD-integrin-binding regions of Tat. Finally, among vaccinees, titers of anti-Tat IgG1, IgG3 and IgG4 subclasses had a significant association with control of viremia in the acute and post-acute phases of infection. Altogether these findings indicate that the Tat/H1D/Alum regimen of immunization holds promise for next generation vaccines with Tat protein or other proteins for which maintenance of the native conformation and activity are critical for optimal immunogenicity. Our results also provide novel information on the role of anti-Tat responses in the prevention of HIV pathogenesis and for the design of new vaccine candidates.
Databáze: MEDLINE
Externí odkaz: